Based on the Metropolis Healthcare Limited stock forecast from 1 analysts, the average analyst target price for Metropolis Healthcare Limited is INR 1,790.00 over the next 12 months. Metropolis Healthcare Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Metropolis Healthcare Limited is Bearish, which is based on 4 positive signals and 10 negative signals. At the last closing, Metropolis Healthcare Limited’s stock price was INR 1,790.40. Metropolis Healthcare Limited’s stock price has changed by -0.81% over the past week, +6.36% over the past month and +42.84% over the last year.
No recent analyst target price found for Metropolis Healthcare Limited
No recent average analyst rating found for Metropolis Healthcare Limited
Company Overview Metropolis Healthcare Limited
Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates. Its tests and profiles are used for prediction, early detection, and diagnosis of the disease. The company also offers corporate wellness and hospital laboratory solutions, as well as clinical research services. Metropolis Healthcare Limited was founded in 1981 and is headquartered in Mumbai, India. Read Less
Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages...Read More
Frequently Asked Questions About Metropolis Healthcare Limited (METROPOLIS:NSE) Stock
Based on ratings from 1 analysts Metropolis Healthcare Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
METROPOLIS:NSE stock's dividend yield is 0.22%.
Our analysis grades METROPOLIS:NSE stock's dividend yield at F. This means that METROPOLIS:NSE stock's dividend yield is above 33% of the stocks in the Diagnostics & Research sector in the NSE exchange.
Based on this METROPOLIS:NSE may be a poor dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for METROPOLIS:NSE is INR 1,790.00 over the next 12 months. The maximum analyst target price is INR 1790 while the minimum anlayst target price is INR 1790.
METROPOLIS:NSE stock's Price/Earning ratio is 75.75.
Our analysis grades METROPOLIS:NSE stock's Price / Earning ratio at F. This means that METROPOLIS:NSE stock's Price/Earning ratio is above 83% of the stocks in the Diagnostics & Research sector in the NSE exchange.
Based on this METROPOLIS:NSE may be a overvalued for its sector.
The last closing price of METROPOLIS:NSE's stock was INR 1,790.40.
The most recent market capitalization for METROPOLIS:NSE is INR 94.33B.
Based on targets from 1 analysts, the average taret price for METROPOLIS:NSE is projected at INR 1,790.00 over the next 12 months.
This means that METROPOLIS:NSE's stock price may go down by -0.02% over the next 12 months.
We can't find any ETFs which contains Metropolis Healthcare Limited's stock.
As per our most recent records Metropolis Healthcare Limited has 4,300 Employees.
Metropolis Healthcare Limited's registered address is 250-D, Udyog Bhavan, Mumbai, India, 400030.
You can get more information about it from Metropolis Healthcare Limited's website at https://www.metropolisindia.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for METROPOLIS:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
